Advancing novel immunotherapeutics to treat infectious disease and cancer

Our Product Pipeline

Vaccines for Infectious Disease

We are developing PIKA-based vaccines to prevent or treat infectious disease, including COVID 19, hepatitis B, rabies and flu.


Immuno-Oncology Therapeutics

Our PIKA-based I-O candidates have shown potent antitumor effects in advanced solid tumors in preclinical studies.


About Us

YS Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a series of preventive and therapeutic biologics targeting Rabies, Hepatitis B, Shingles, influenza, Coronavirus. YS Biopharma operates in China, Singapore, the United States, the United Arab Emirates and the Philippines with over 800 employees and led by a management team that combines rich local expertise and global vision in the vaccine and pharmaceutical industry.

PIKA Technology

Developing Diverse Biotherapeutics Based on TLR3, RIG-I and MDA5 Activation

PIKA technology consists of biologic complexes that incorporate an agonist of multiple pathways of immune signaling: TLR3, RIG-I and MDA5. When delivered with relevant protein-based molecules, PIKA technology is offering a promising platform for the development of a wide variety of novel biotherapeutics as new generation of antiviral vaccines, antiviral therapeutics and anticancer therapeutics.

We are Happy To Connect

Don't Hesitate To Connect